AstraZeneca   2Q Revenues: $6.2 billion (-4%) 2Q Earnings: $823 million (-24%) YTD Revenues: $12.6 billion (-10%) YTD Earnings: $1.8 billion (-26%) Comments: Loss of exclusivity on several key brands accounted for approximately $500 million in lost revenue in the quarter. U.S. revenues were down 4%, largely driven by erosion of Seroquel IR. ROW was also down 4%. Revenue in Europe was down 13%, driven by the loss of exclusivity for Atacand, Nexium, and Seroquel IR. Crestor sales were down 4% ...